Medical Technologies announced today that its sensory insoles, analytics platform, and remote monitoring program will be used in a new clinical trial funded by the National Institutes of Health (NIH).
Expanded Science and Discovery Program onboard Ultramarine: Launched on World Voyager in Antarctic 2026/2027, the Science & ...
Thank you, Michael, and welcome to our third quarter 2025 earnings call. Ensuring we remain the home of the free in the land ...
Good day, ladies and gentlemen, and welcome to your Capstone Green Energy Earnings Conference Call and Webcast for the financial results for the second quarter fiscal year 2026 ended on September 30, ...
Q3 2025 Earnings Call November 13, 2025 8:00 AM ESTCompany ParticipantsThomas Schulz - Chairman of Executive Board & ...
2025 Revenue Guidance -- Management expects full-year revenue of $30 million to $40 million, with Q4 guidance of $5 million ...
Delcath Systems, Inc. , ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results ...
Ignacio José Calomarde Heras, Francisco Milán Cabrera, Alberto Villarrubia de Juan, Miguel Ángel De Frutos Carro, UAV ...
The killer and his victim were strangers who met by chance and had shared a beer at the campsite before things took a dark ...
Some scientists argued that autism-gut microbiome research is rife with conceptual and methodological flaws, from mouse to ...
DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Positive Interim ...
DARE to PLAY Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product RevenuePositive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Contin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback